PULSE: using space to build better heart models and study cardiac ageing

World Population Day focuses attention on demographic shifts that matter for policy and biomedical research. Global life expectancy rose from approximately 64.6 years in the early 1990s to 72.6 years in 2019. Longer lives increase the prevalence of age related diseases and place growing pressure on health systems. Among these conditions cardiovascular disease remains the leading cause of death worldwide and its burden rises sharply with age. PULSE is an EIC Pathfinder project that proposes a novel route to study cardiac ageing by exploiting microgravity to produce complex three dimensional cardiac tissue models that are difficult or impossible to fabricate on Earth.

What PULSE aims to do

Coordinated by Maastricht University, PULSE aims to develop a radical new bioprinting approach based on multiple levitation principles. The headline claim is that microgravity allows scaffold free, label free, and nozzle free assembly of engineered cardiac constructs with complex internal geometries and fluidic channels. These constructs are intended as advanced in vitro models for studying mechanisms of cardiac ageing and for testing candidate anti ageing interventions such as anti inflammatory or antioxidant drugs.

How the technology differs from Earth based bioprinting

On Earth, bioprinting usually relies on extruded bio inks, supporting scaffolds or hydrogels and nozzle deposition. Those methods impose limitations on geometry, pore architecture and the mechanical environment experienced by embedded cells. PULSE’s route is an experimental attempt to overcome some of those constraints by moving the assembly step into a low gravity environment and substituting contact deposition with levitation based positioning.

Progress to date and planned tests

According to project updates the team has designed, manufactured and assembled a first prototype of the magneto acoustic levitation device. That prototype is being finalised for ground testing and validation ahead of space qualification. An adapted design was prepared for a parabolic flight in October 2025 to provide intermediate microgravity exposure and to simulate the stresses of launch and short microgravity intervals. The consortium has also advanced hydrogel selection for cardiovascular cells and reports preliminary data examining radiation and microgravity effects on heart organoids. The project’s public timeline indicates a planned ISS mission in 2027.

Scientific rationale and early data

The rationale for moving some aspects of tissue engineering into space rests on two claims. First, microgravity permits assembly of more complex architectures and gentler handling of cells. Second, exposing tissues to the combined stressors of microgravity and cosmic radiation may accelerate certain cellular and tissue level processes that resemble aspects of ageing. PULSE positions itself explicitly as using space as an accelerator of ageing research on Earth, with cardiac tissue models intended to provide new mechanistic insights and a platform for testing anti ageing candidates.

The team has also presented early results on the responses of heart organoids to radiation and short microgravity exposures. These preliminary findings are an important step but they are early stage. Organoid responses to radiation and transient microgravity are complex and can differ from the chronic, multifactorial process of natural ageing. Robust claims about therapeutic screening or predictive power require larger data sets, repeated missions or validated ground based analogues to establish reproducibility.

Consortium, scope and intended impact

PULSE is coordinated by Maastricht University and involves eight partners from seven countries. Public project pages and community coverage list partner countries including Austria, Belgium, Denmark, Germany, Italy, the Netherlands and Portugal. The project frames impact across several domains: improved models for cardiac physiology and pathology; potential drug testing platforms that could reduce reliance on animal experiments; direct relevance to astronaut health during long duration missions and implications for patients exposed to ionising radiation such as some cancer therapies.

Technical and translational caveats

The PULSE approach is technically ambitious. A number of practical and interpretive challenges deserve emphasis when evaluating the project’s prospects.

First, microgravity induced changes are not identical to the complex biology of chronological ageing. Microgravity and radiation produce specific stress profiles that can mimic some cellular hallmarks of ageing such as oxidative stress or senescence. They can also produce unique phenotypes not seen in normal ageing. That makes the term ageing accelerator imprecise and risks over interpretation of space induced effects as direct models of human heart ageing.

Second, reproducibility and scaling are open questions. Space experiments are expensive and logistically constrained which limits sample sizes and repeat experiments. To be useful for drug screening a platform must be reproducible, high throughput or closely coupled to validated Earth based controls.

Third, radiation in low Earth orbit and in deep space differs in quality and dose from clinical exposures and environmental ageing. Disentangling radiation mediated effects from microgravity mediated effects requires careful controls and dosimetry data.

Regulatory, ethical and commercial considerations

If PULSE succeeds in producing reproducible, physiologically relevant cardiac constructs, several non technical hurdles remain. Regulators will need to be satisfied that data generated on space printed tissues translate to human outcomes. For drug testing and preclinical decision making, regulatory bodies such as the European Medicines Agency will require validation studies and alignment on endpoints. There are also ethical considerations around human derived cells, data sharing and animal replacement claims that must be handled with transparency.

Commercialisation will require a path from expensive, low throughput space experiments to scalable services or validated Earth based proxies. That could involve industry partnerships, national space agency co funding or spin outs that adopt hybrid approaches combining space derived design principles with terrestrial manufacturing methods.

What PULSE could change and what remains uncertain

At best the project will yield new design rules for tissue architecture, bio ink chemistries and scaffold free assembly that accelerate better models on Earth. Those advances could reduce reliance on animal tests and provide more human relevant platforms for mechanistic studies and preclinical screening. They may also inform countermeasures for astronaut cardiovascular health and improve understanding of how radiation affects human tissues.

At worst, the work may demonstrate interesting space specific phenomena that are hard to reproduce or translate, leaving limited immediate benefit for Earth bound drug development. The distinction depends on the rigor of controls, the scale of validation and the consortium’s ability to engage regulators and industry early.

Recommendations and next steps for the project and funders

For the science to deliver usable outcomes PULSE and similar projects should prioritise the following actions.

1. Standardised ground controls. Run matched Earth based experiments that replicate materials, cell sourcing, culture timelines and radiation exposures where possible to interpret which effects arise from microgravity specifically.

2. Reproducibility plans. Publish detailed protocols, quality control metrics and raw data early so other groups can attempt replication and meta analysis.

3. Regulatory engagement. Start early discussions with EMA and national regulators about validation pathways for tissue models intended for drug screening or safety testing.

4. Path to scale. Develop a commercial strategy that identifies how space derived designs can either be produced more economically on Earth or offered as a high value, niche service for specific research customers.

5. Ethical and transparency safeguards. Clarify sourcing of human cells, consent provisions and data sharing agreements and avoid premature claims about replacing animal testing until robust validation is complete.

Context within the EU innovation ecosystem

PULSE is an example of the European Innovation Council’s push to back high risk, frontier research that could spawn new tech clusters. The EIC Pathfinder aims to bridge bold ideas and demonstrators. Projects like PULSE benefit from EIC Business Acceleration Services to connect with industry, investors and regulatory advice as they move past proof of concept. However such projects also underscore the long and uncertain path from demonstration to routine clinical or commercial use and the need for staged funding and partnership strategies across Horizon instruments, national agencies and industry.

Conclusion

PULSE is scientifically interesting and technically bold. It brings together biomaterials, space engineering and cardiovascular biology to explore whether microgravity can expand what is technically feasible in tissue architecture and accelerate certain biological readouts relevant to ageing. The project has delivered early hardware and material selection milestones and is preparing for microgravity tests. That progress is notable given logistical complexity.

Claims that space will act as a straightforward accelerator of ageing research should be treated with caution. Microgravity and radiation produce particular stress responses that are not identical to human ageing. The real test will be whether PULSE produces reproducible, validated constructs and data that improve predictive power for therapies on Earth or deliver unique insights for astronaut health. Achieving that will require rigorous controls, transparent data, regulatory engagement and a credible route to scale.

Readers who want more technical detail can consult the Horizon Europe project entry for grant 101099346 or follow consortium publications as the project completes parabolic flight tests and moves toward ISS experiments.